Lumos Pharma, Inc. (LUMO) Earnings Call Transcript & Summary

Good morning, and welcome to the Lumos Pharma virtual shareholder meeting. [Operator Instructions] I would now like to introduce you to Richard J. Hawkins, Chief Executive Officer, President and Chairman of the Board.

Good morning. I'm Rick Hawkins. I'm Chief Executive Officer, President and Chairman of Lumos Pharma. I'm very happy to welcome you to the Lumos Pharma 2021 stockholders' [indiscernible]. Before I call the meeting to order, I'd like [ to introduce ] you to members of the management team who are with us [indiscernible]. [ In addition ] to myself, the other executive officers of the company here today are John McKew, [ Chief Operating Officer and Chief Scientific Officer ]; Carl Langren, [ Chief Financial Officer; Aaron Schuchart, Chief Business Officer ]; and Lori Lawley, Senior VP [indiscernible] also like to introduce you Brad Powers, General Counsel, who has been appointed [ recording secretary for ] [indiscernible]. In addition, I'd like to introduce Cameron Brown of KPMG, the company's auditors; and [ Rob Suffoletta ] of Wilson Sonsini, legal counsel to the company, who are available to respond to appropriate questions. The meeting will now officially come to order. We will proceed with the formal business of the meeting as set forth in the notice [ of the annual meeting and proxy statement ]. After the formal part of our meeting, we'll give you an opportunity to ask any questions [indiscernible]. Will the secretary please report at this time with respect [ to ] mailing of the notice of the meeting and the stockholders list?

I have at this meeting a complete list of stockholders of record of the company's common stock on March 22, 2021, the record date for this meeting. I also have an affidavit certifying that, on or about April 9, 2021, a notice of the Annual Meeting of Stockholders of the company was deposited in the United States mail to all stockholders of record at the close of business on March 22, 2021.

At this time, I'd like to introduce Ryan Trytten, who is Lumos' Senior Manager of SEC Reporting and Legal Affairs. I'm appointing Mr. Trytten to act as inspector of election at this meeting. Mr. Trytten has taken and subscribed to the customary oath of office to execute his duties with strict impartiality. We will file this oath with the records of the meeting. His function is to decide upon the qualifications of voters; accept their votes; and when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum?

I have been informed by the inspector of election that proxies have been received for 5,944,657 of the 8,332,193 shares of common stock outstanding on the record date, which represents approximately 71% of the total number of outstanding shares. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.

We'll now proceed with the formal business of this meeting. There are 3 proposals to be considered by the stockholders at this meeting.

The time is now 11:04 a.m. on Wednesday, May 19, 2021, and the polls are now open for voting on all matters to be presented. The polls will be closed to voting after we go through the matters to be voted on.

The first item of business is the election of 2 Class III directors to serve until the 2024 annual meeting and until their successors are elected. 2 Class III directors, Chad Johnson and Lota Zoth, have each been [indiscernible] by our Nominating and Governance Committee and our Board for [indiscernible]. We now turn to election of our Class III director candidates as set forth in the proxy statement. The nominees for Class III directors are Chad Johnson and Lota Zoth. Is there any discussion?

There is no discussion at the moment.